CDX Prostate
Commercial- Indications
- Prostate cancer
Company intelligence / Profile preview
Protean BioDiagnostics offers rapid precision oncology diagnostics with results in as little as one day. Their CLIA-certified labs provide comprehensive molecular profiling, digital pathology with AI assessment, genetic risk testing, and telemedicine-enabled tumor boards. They have recently partnered to launch CDX Prostate for aggressive prostate cancer screening in the US. The company supports both community oncologists and academic centers with advanced data integration tools and maintains an active research program focused on closing gaps in access to cutting-edge cancer care.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Protean BioDiagnostics.